Các đặc điểm lâm sàng và xét nghiệm liên quan đến ung thư ở bệnh nhân viêm đường mật nguyên phát: một nghiên cứu dựa trên khảo sát theo chiều dọc

Carey EJ, Ali AH, Lindor KD (2015) Primary biliary cirrhosis. Lancet. 386(10003):1565–1575 Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132 Hemminki K, Sundquist K, Sundquist J, Ji J (2015) Risk of cancer of unknown primary after hospitalization for autoimmune diseases. Int J Cancer 137(12):2885–2895 Fang YF, Wu YJ, Kuo CF, Luo SF, Yu KH (2016) Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol 35(8):1977–1984 Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL et al (2016) Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 65(2):321–329 Zhang XX, Wang LF, Jin L, Li YY, Hao SL, Shi YC, Zeng QL, Li ZW, Zhang Z, Lau GK, Wang FS (2015) Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors. World J Gastroenterol 21(12):3554–3563 Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF (1997) Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 26(5):1138–1142 Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T, Nakanuma Y (2013) Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 57(5):1942–1949 Liang Y, Yang Z, Zhong R (2012) Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology. 56(4):1409–1417 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver Diseases (2009) Primary biliary cirrhosis. Hepatology. 50(1):291–308 Heathcote EJ (2000) Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 31(4):1005–1013 Harada K, Nakanuma Y (2014) Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis. Hepatol Res 44(2):133–140 Su CW, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Lee PC, Lee SD, Wu JC (2008) Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int 28(9):1305–1313 Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ (2008) Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 20(1):5–9 van der Deure WM, Lugtenburg EP, Dwarkasing RS, Biermann K, Tjwa ET (2015) Malignancy presenting as multiple lesions in a cirrhotic liver: not always hepatocellular carcinoma. J Gastrointest Liver Dis 24(1):7 Kaneko H, Endo T, Saitoh H, Katsuta Y, Aramaki T, Hayakawa H (1993) Primary biliary cirrhosis associated with multiple myeloma. Intern Med 32(10):802–805 Rodriguez-Leal GA, Moran-Villota S, Arista-Nasr J, Uribe-Esquivel M (1997) Case report of multiple myeloma and hypothyroidism in primary biliary cirrhosis. Rev Investig Clin Organo Hosp Enferm Nutr 49(3):215–220 Blade J, Montserrat E, Bruguera M, Aranalde J, Granena A, Cervantes F et al (1981) Multiple myeloma in primary biliary cirrhosis. Scand J Haematol 26(1):14–18 Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Chen Y, An L, Yang Y, Gershwin ME (2015) Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol 48(2-3):132–141 Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D et al (2009) Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 50(4):1162–1168 Pawelec G, Derhovanessian E, Larbi A (2010) Immunosenescence and cancer. Crit Rev Oncol Hematol 75(2):165–172 Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheum 67(4):1053–1061 Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, Meyer W, Bogdanos DP, Sakkas LI (2017) Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 50(7):414–421 Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP (2013) Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 37(6):572–585 Lee KE, Kang JH, Lee JW, Wen L, Park DJ, Kim TJ, Park YW, Lee SS (2015) Anti-centromere antibody-positive Sjogren's syndrome: A distinct clinical subgroup? Int J Rheum Dis 18(7):776–782 Hamaguchi Y (2010) Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 37(1):42–53 Iniesta Arandia N, Simeon-Aznar CP, Guillen Del Castillo A, Colunga Arguelles D, Rubio-Rivas M, Trapiella Martinez L et al (2017) Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol 35(Suppl 106(4)):98–105 Freeman S (2012) Scleroderma malignancy risk linked to antinuclear antibodies Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K (2000) Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19(2):123–126 Fuschiotti P, Medsger TA Jr, Morel PA (2009) Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 60(4):1119–1128 Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, Gong S, Podda M, Invernizzi P (2010) Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol 10:100